Abstract: A treatment for symptoms of migraine and cluster headaches includes operations of providing a solution of a serotonin receptor agonist (SRA) in an active mesh nebulizer, triggering the formation of a plume of particles from the active mesh nebulizer, and delivery of the plume of particles into the lungs of a patient during an inhalation process.

Abstract: A method of treating respiratory system tissue, includes operations of generating a plume of particles of a treating solution from a nebulizer, inhaling particles of the treating solution, delaying exhalation of an inhalation having particles of the treating solution therein, and determining whether a dose of the treating solution has been delivered, wherein the treating solution is a solution of at least 40% ethyl alcohol, by volume.

Abstract: An endotracheal tube sound device is presented having a sound bead connected to the distal end of a wire. A retaining piece is affixed to the wire adjacent to the sound bead. A handle is connected to the proximal end of the wire. Using this device, the sound bead may be inserted into an endotracheal tube to determine if the endotracheal tube is deformed and then removed from the endotracheal tube by pulling on the handle.

Abstract: A nebulizer with an active mesh configured to produce a plume of particles for treating medical conditions is activated by a dosage request by a user, produces a plume of particles, at least 95% of which have a diameter between about 0.5 and up to about 5 ?m, and tracks delivery of a pharmacological compound in the plume of particles of nebulized solution. The active mesh is configured to turn on, and turn off, during a single inhalation, and to provide a dose of pharmacological compound over at least one inhalation of at least one plume. The active mesh does not produce a plume of particles when no inhalation occurs, to prevent waste and to ensure accurate dosing of pharmacological compound. The nebulizer blocks use of the active mesh when a dosage limit is met, and enables use of the active mesh when a dosing delay time has passed.

Abstract: A method of delivering a medication or a pharmaceutical product to a patient includes operations of activating an active mesh of an active mesh nebulizer, the active mesh being in contact with a liquid formulation of the medication, and configured to generate a plume of particles having a particle diameter between 1 and 6 micrometers, directing the plume of particles to a mouth of a patient during an inhalation by a patient; and stopping the plume of particles during the inhalation by the patient such that a substantial majority, or nearly all, of the plume of particles is inhaled by the patient.

Abstract: An aqueous nicotine solution for use in an active mesh nebulizer as part of a smoking cessation program, or as a substitute for tobacco use, includes nicotine in water with a nicotine concentration ranging from about 1.0 milligram (mg) nicotine per milliliter (ml) of water (e.g., 0.01% nicotine), to about 0.005 mg nicotine per milliliter of water (about 0.0005% nicotine). The pH of the aqueous nicotine solution ranges from about 3.5 to about 12 because the plume of particles of aqueous nicotine solution produced by the active mesh nebulizer are entrained with the inhaled air and do not impact the walls of the throat or lungs. The aqueous nicotine solution is free from metals because it is delivered to a user at room temperature, without heating or boiling.

Abstract: An active mesh nebulizer is used to generate a distribution of liquid particles or droplets having a diameter ranging from about 0.5 to about 5 micrometers (?m). Delivery and ingestion, by inhalation, of ethyl alcohol solution particles leads to rapid uptake of the alcohol solution by brain tissue, and avoids damage to the liver, gastrointestinal tract, and/or peripheral nervous system consistent with drinking ethyl alcohol. A brain effect of ethyl alcohol absorbed through alveoli in the lung occurs within less than 60 seconds, and body effects of alcohol consumption are reduced or eliminated. Delivery of ethyl alcohol to a user by absorption through alveoli provides a user with a brain effect while allowing tissue damage from drinking alcohol to heal. A lock out barcoded capsule containing ethyl alcohol, tethered to a smartphone application, prevents unauthorized use by non-designated users, or abuse by a designated user.

Abstract: An active mesh nebulizer is used to generate a distribution of liquid particles or droplets having a diameter ranging from about 0.5 to about 5 micrometers (?m). Delivery and ingestion, by inhalation, of ethyl alcohol solution particles leads to rapid uptake of the alcohol solution by brain tissue, and avoids damage to the liver, gastrointestinal tract, and/or peripheral nervous system consistent with drinking ethyl alcohol. A brain effect of ethyl alcohol absorbed through alveoli in the lung occurs within less than 60 seconds, and body effects of alcohol consumption are reduced or eliminated. Delivery of ethyl alcohol to a user by absorption through alveoli provides a user with a brain effect while allowing tissue damage from drinking alcohol to heal. A lock out barcoded capsule containing ethyl alcohol, tethered to a smartphone application, prevents unauthorized use by non-designated users, or abuse by a designated user.

Abstract: In essence, the present invention relates to a medical product containing a normal saline solution and about 1/8th of 1 milligram and 3 milligrams of nicotine. The medical product may also include about 1% to 3% of flavor such as tobacco, menthol and hazelnut. The medical product may also include about 1 to 3 microns that are drawn through an entrainment port, a capsule, the grid and into the individual's lungs and their bloodstream. The present invention is also used for patients who want to maintain the benefits of nicotine such as alertness, memory retention, relaxation, maintaining normal bowel movement, and avoidance of weight gain, without the health risks of tobacco ingredients. It may also be used as a method to initiate weight loss in obese individuals as part of a plan including diet and exercise.

Abstract: A nebulizer comprising a nebulizing chamber with a vibrating mesh grid having a plurality of precision openings and said chamber with a liquid pharmaceutical product in a cartridge contacting the mesh grid for producing particle sizes of two (2) to four (4) microns; and an entrainment port for drawing air into the nebulizing chamber and through the grid. A control circuit, a source of electrical energy in said circuit such as two 1.5 volt lithium titanate batteries connected to said grid for producing vibration. A switch to turn said grid off and on and means for providing a first measured time period of four seconds for taking a first breath of air through the entrainment port and grid and through the thousands of passageways into the lungs and bloodstream of an individual. A second time period during which no vibration occurs. The grid is also self-cleaning as described.

Abstract: In essence, the present invention relates to a medical product including between about 94% and about 98% of a saline solution, preferably a normal saline solution containing about 0.9% sodium chloride dissolved in water, about ?th of 1 milligram of relatively pure nicotine and about 3 milligrams of relatively pure nicotine. The medical product also includes about 1% and 3% of one or more flavors selected from the group consisting of citrus, tobacco, apple, cherry, maple, menthol, hazelnut, peach, lemon, vanilla and chocolate and 1% citric acid for taste. In addition, the medical product includes about 1% to 2% of ethyl alcohol for cleaning a micron mesh grid that generates particles of pure nicotine of from 2 to 5 microns that are drawn through an entrainment port, through a capsule containing the medical product through the micron mesh grid and into the individual's lungs and into their bloodstream.

Abstract: In essence, the present invention relates to a medical product including between about 94% and about 98% of a saline solution, preferably a normal saline solution containing about 0.9% sodium chloride dissolved in water, about ?th of 1 milligram of relatively pure nicotine and about 3 milligrams of relatively pure nicotine. The medical product also includes about 1% and 3% of one or more flavors selected from the group consisting of citrus, tobacco, apple, cherry, maple, menthol, hazelnut, peach, lemon, vanilla and chocolate and 1% citric acid for taste. In addition, the medical product includes about 1% to 2% of ethyl alcohol for cleaning a micron mesh grid that generates particles of pure nicotine of from 2 to 5 microns that are drawn through an entrainment port, through a capsule containing the medical product through the micron mesh grid and into the individual's lungs and into their bloodstream.

Abstract: A pulmonary delivery system includes an elongated body having an openable and closeable portion thereof for receiving an insertable and replaceable container such as a cartridge of pure medical product disposed in a saline solution. The medical product may be epinephrine, insulin or nicotine disposed in a saline solution. The system also incorporates a penetrating element that is disposed in the cylinder to pierce the cartridge and release the nicotine solution into the cylinder and into or on a micron mesh grid. A flow of air created by inhaling through a mouthpiece draws air into an individual's lungs from an entrainment port and onto a grid for atomizing a mist of micron droplets through the grid. It is recognized that the air from the entrainment port further dilutes the concentration of the medical product. The grid is connected to a source of electrical power to vibrate the mesh grid.

Abstract: A nebulizer in accordance with the present invention comprises a nebulizing chamber including a vibratable micro micron mesh grid having a plurality of precision openings and passageways therethrough disposed in said chamber with a liquid pharmaceutical product contained in said nebulizing cartridge and passing through said openings in said vibratable micro micron mesh grid for producing particle sizes of said pharmaceutical product of about two (2) to five (5) microns; and an entrainment port for drawing air into and through the entrainment port into the nebulizing chamber and through the grid. A control circuit, a source of electrical energy in said circuit such as two 1.5 volt nickel cadmium batteries connected to said grid for producing vibration.

Abstract: A kink resistant silicon endotracheal tube includes an inflatable cuff for positioning the endotracheal tube in a patient's trachea. The cuff is folded over onto itself to provide a cavity for accumulating bacteria and secretions that are then removed by suction. The cuff in the lower part of the endotracheal tube is also folded over onto itself for centering the endotracheal tube in the center of an airway. A suction catheter is also positioned in a portion of the tube under tension as opposed to a portion under compression to reduce the likelihood of kinking. A kink resistant endotracheal tube also includes a thickened and/or reinforced area of the curved portion of the endotracheal tube in an area under compression.

Abstract: A kink resistant silicon endotracheal tube includes an inflatable cuff for positioning the endotracheal tube in a patient's trachea. The cuff is folded over onto itself to provide a cavity for accumulating bacteria and secretions that are then removed by suction. The cuff in the lower part of the endotracheal tube is also folded over onto itself for centering the endotracheal tube in the center of an airway. A suction catheter is also positioned in a portion of the tube under tension as opposed to a portion under compression to reduce the likelihood of kinking. A kink resistant endotracheal tube also includes a thickened and/or reinforced area of the curved portion of the endotracheal tube in an area under compression.

Abstract: A method for optimizing the breathing ability of an intubated patient is based on an evaluation of the expirational flow characteristics of an endotracheal tube connector. It has been found that an increase in the amount of work required for the expirational portion of the breathing cycle while minimizing the inspirational work of a patient improves the patient's blood chemistry and the absorption of oxygen and/or medication by the lung.The method may be obtained by using an improved connector which includes an annular gas inlet and an annular gas outlet which share a common longitudinal axis. The inlet has an inside diameter which is about 2-1/2 to 3 times greater than the inside diameter of the outlet and is adapted to receive a flexible tube having an outside diameter which is approximately the same as the inside diameter inserted therein.

Abstract: An endotracheal tube construction includes an elongated kink resistant flexible tubular member having distal and proximal ends with a curved portion therebetween. The tubular member defines a major passageway or airway and a relatively small cuff inflating lumen which is parallel to the major passageway and disposed in the wall of the tubular member. The cuff inflating lumen is positioned within a portion of the wall which is subjected to tension as the tubular member is bent as opposed to being positioned in that portion of the wall which is under compression. In addition, the portion of the wall adjacent to the lumen is thicker than the wall in other portions of the tube so that the tube is less likely to kink or collapse during intubation of a patient. The endotracheal tube includes a beveled tip and is constructed and arranged so that the beveled tip can be rotated by twisting a portion of the tube which extends out of a patient's mouth or nose without kinking or collapsing the tube.

Abstract: Endotracheal apparatus including an endotracheal tube having unique physical characteristics so that it will not kink or collapse during intubation or while in place. A novel cuff or balloon is on the distal end region of the tube to accurately center the tube end in the trachea without danger that the open distal end of the tube will contact the trachea wall, and to permit the minimum length tube to be used. A novel bite piece and retainer is used to secure the tube in the patient's mouth with optimum comfort.

Abstract: An improved connector for coupling an endotracheal tube or the like to a source of gas is disclosed. The connector has an inside diameter which is 21/2 to 3 times greater than the inside diameter of the outlet and is adapted to receive a flexible tube therein. The connector also includes an intermediate portion defining a radially flared outwardly extending annular passageway and a shoulder adjacent to the larger end of the radially flared passageway. The shoulder has a width which is approximately equal to the wall thickness of the flexible tube.